KalVista Pharmaceuticals, Inc.
- KALV
- NASDAQ
- Biotechnology
- Plasma Kallikrein Inhibitors
- Small Molecule Drugs (Hereditary Angioedema)
$27.00
Quote Jun 10, 2026, 08:00 PM UTC
+0.75%over the last month
Max drawdown −0.3%From 1-month high 0.0%3 months +59.4%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About KalVista Pharmaceuticals
KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: Sebetralstat for HAE and Factor XIIa.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
275
Market value
$1.44B
Quote Jun 10
Analyst target
$27.00
+0.0% from here
Floor
$26.78
0.8% below price
Resistance
$27.03
0.1% above price
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about KALVPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free